Wednesday, 21 December 2016

Biogen Faces No Easy Opportunities

The biotech’s risks run deeper than the outcome of its Alzheimer’s trial.

from WSJ.com: Markets http://ift.tt/2hR1XgH
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)